These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36282666)

  • 1. [The 1998 default and the pharmaceutical market. Report 2: Predictions and Estimates].
    Zatravkin SN; Vishlenkova EA; Ignatiev VG
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2022 Sep; 30(5):903-908. PubMed ID: 36282666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The default of 1998 and pharmaceutical market. Report I. The chronicle of disaster.
    Zatravkin SN; Ignatiev VG; Vishlenkova EA
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2022 Jul; 30(4):683-691. PubMed ID: 35960302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The Russian pharmaceutical branch in 1990s. Report 1. From the Soviet to the market].
    Zatravkin SN; Vishlenkova EA; Ignatiev VG
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2022 Jan; 30(1):160-166. PubMed ID: 35157399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The Renaissance of Russian pharmaceutical market (2000-2004). Report I. The field players].
    Zatravkin SN; Vishlenkova EA; Ignatiev VG
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2022 Dec; 30(6):1358-1366. PubMed ID: 36541323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The Russian pharmaceutical industry in 1990s. Report III. Insider vision].
    Zatravkin SN; Vishlenkova EA; Ignatiev VG
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2022 May; 30(3):503-507. PubMed ID: 35670410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The Renaissance of Russian pharmaceutical market (2000-2004). Report III. The interests of consumers].
    Zatravkin SN; Vishlenkova EA; Ignatiev VG
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2023 Mar; 31(2):290-296. PubMed ID: 37129405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The Renaissance of Russian pharmaceutical market (2000-2004). Report II. The Pharma servants of Russia].
    Zatravkin SN; Vishlenkova EA; Ignatiev VG
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2023 Jan; 31(1):112-119. PubMed ID: 36801885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The Russian pharmaceutical branch in 1990s. Report II. The optics of external observers].
    Zatravkin SN; Vishlenkova EA; Ignatiev VG
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2022 Mar; 30(2):322-328. PubMed ID: 35439398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacy in Latvia during the first Soviet occupation (1940-1941).
    Lauze S; Mauriņa B; Šidlovska V
    Pharmazie; 2019 Aug; 74(8):505-510. PubMed ID: 31526445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Early achievements of the Danish pharmaceutical industry-7].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2014; (42):31-62. PubMed ID: 25816561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patent indicators: a window to pharmaceutical market success.
    Guo Y; Hu Y; Zheng M; Wang Y
    Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Russian-American pharmaceutical relations, 1900-1945.
    Conroy MS
    Pharm Hist; 2004; 46(4):143-66. PubMed ID: 15991449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacy and drug industry for the 25 years of Soviet Government in Azerbaijan].
    ALIEV RK
    Farmacia; 1946; 9(1):9-11. PubMed ID: 20290412
    [No Abstract]   [Full Text] [Related]  

  • 15. [Early achievements of the Danish pharmaceutical industry-6 Pharmacia].
    Grevsen JV; Kruse E; Kruse PR
    Theriaca; 2014; (42):9-30. PubMed ID: 25816560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Companies' statements about drugs withdrawn from the Canadian market: A descriptive analysis.
    Lexchin J
    Int J Risk Saf Med; 2021; 32(4):331-341. PubMed ID: 34057099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health professional's exposure, attitude, and acceptance of drug promotion by industry representatives: A cross-sectional study in Ethiopia.
    Yimenu DK; Demeke CA; Kasahun AE; Siraj EA; Wendalem AY; Bazezew ZA; Atsbeha BW; Mekuria AB
    Sci Prog; 2021; 104(2):368504211029435. PubMed ID: 34191639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of pharmaceutical representative visits and medication samples in community-based family practices.
    Backer EL; Lebsack JA; Van Tonder RJ; Crabtree BF
    J Fam Pract; 2000 Sep; 49(9):811-6. PubMed ID: 11032205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical markets regulation overview of the selected European Union countries.
    Pogorzelczyk K; Synoweć J; Robakowska M; Ślęzak D; Holajn P; Robakowski P; Żuratyński P; Nadolny K
    Wiad Lek; 2018; 71(7):1404-1408. PubMed ID: 30448818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmaceutical economics and socialistic organization. 19. Needs and demands of the drug internal market].
    Seidlein HJ
    Pharm Prax; 1970; 11():241-7. PubMed ID: 5494136
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.